Nachrichten zu Eyenovia

Startseite > Aktien > Eyenovia > Nachrichten

Eyenovia Aktie

Aktie

ISIN: US30234E1047 WKN: A2N6DV SYM: EYEN Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,5367

USD

-1,00 %

-0,0054 USD

Letzter Kurs 14.09.24 Nasdaq

Geldkurs

13.09.24

0,5351

USD

2.000 STK

Briefkurs

13.09.24

0,5399

USD

2.800 STK

Eyenovia Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. 05.09.24 · globenewswire · Eyenovia
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer 03.09.24 · globenewswire · Eyenovia
Eyenovia Announces Closing of Public Offering 23.08.24 · globenewswire · Eyenovia
Eyenovia Announces Pricing of $5.14 Million Public Offering 21.08.24 · globenewswire · Eyenovia
Eyenovia, Inc. Announces Proposed Public Offering 20.08.24 · globenewswire · Eyenovia
Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference 13.08.24 · globenewswire · Eyenovia
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update 12.08.24 · globenewswire · Eyenovia
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th 08.08.24 · globenewswire · Eyenovia
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. 07.08.24 · globenewswire · Eyenovia
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease 30.07.24 · globenewswire · Eyenovia
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease 23.07.24 · globenewswire · Eyenovia
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities 01.07.24 · Business Wire (engl.) · Eyenovia

1
2
…
3

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate ... 420 Leser
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as ... 368 Leser
Eyenovia, Inc. Announces Proposed Public Offering 328 Leser
Eyenovia Announces Pricing of $5.14 Million Public Offering 216 Leser
Eyenovia Announces Closing of Public Offering 216 Leser

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III ... 472 Leser
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update 432 Leser
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate ... 420 Leser
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th 372 Leser
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th 372 Leser
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as ... 368 Leser
Eyenovia, Inc. Announces Proposed Public Offering 328 Leser
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value ... 328 Leser
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility 236 Leser
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th 232 Leser